NCT04426357 is a Phase 1 clinical trial of JNJ-64417184 in Renal Impairment, sponsored by Janssen Pharmaceutica N.V., Belgium.

Who is sponsoring NCT04426357?

NCT04426357 is sponsored by Janssen Pharmaceutica N.V., Belgium.

What drugs are being tested in NCT04426357?

Interventions in NCT04426357: JNJ-64417184.

What condition does NCT04426357 study?

NCT04426357 studies Renal Impairment.

Is NCT04426357 still recruiting?

NCT04426357 is currently terminated. Last updated 15 January 2021.

Last reviewed 2021-01-15 · How we verify

NCT04426357

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Terminated Phase 1 Last updated 15 January 2021

What this trial tests

Phase 1 trial testing JNJ-64417184 in Renal Impairment in 6 participants. Terminated before completion.

Timeline

3 July 2020

Primary endpoint
12 November 2020

12 November 2020

Quick facts

Lead sponsor	Janssen Pharmaceutica N.V., Belgium
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	6
Start date	3 July 2020
Primary completion	12 November 2020
Estimated completion	12 November 2020
Sites	2 locations across Germany

Drugs / interventions tested

JNJ-64417184

Conditions studied

Renal Impairment — all drugs for Renal Impairment →

Sponsor

Janssen Pharmaceutica N.V., Belgium — full company profile →

Who can join

Adults 18 to 79, any sex, with Renal Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the pharmacokinetics of JNJ-64417184, JNJ-68294291, and JNJ-65201526 after a single oral dose of JNJ-64417184 in adult participants with various degrees of impaired renal function (moderate \[optional\], severe renal impairment, and end stage renal disease (ESRD) not requiring hemodialysis) compared to participants with normal renal function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of JNJ-64417184

Trials testing the same drug.

NCT04453189 — A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants · Phase 1 · completed
NCT04258189 — A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants · Phase 1 · completed
NCT04208373 — A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants · Phase 1 · completed
NCT04121052 — A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administe · Phase 1 · completed
NCT04090086 — A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Particip · Phase 1 · completed

Other recruiting trials for Renal Impairment

Currently open trials in the same condition.

NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
NCT07315360 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function · Phase 1 · recruiting
NCT07217886 — A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls · Phase 1 · recruiting
NCT07154901 — Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD23 · Phase 1 · recruiting
NCT07017933 — Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes · NA · recruiting

Other Janssen Pharmaceutica N.V., Belgium trials

Trials by the same sponsor.

NCT06544616 — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease · Phase 2 · active not recruiting
NCT05706753 — A Study of Milvexian in Healthy Adult Females · Phase 1 · completed
NCT05550519 — A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatm · EARLY_PHASE1 · withdrawn
NCT05552196 — A Study of Ponesimod in Healthy Adult Participants · Phase 1 · completed
NCT05328297 — A Study of JNJ-55308942 in the Treatment of Bipolar Depression · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04426357 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Pharmaceutica N.V., Belgium
Last refreshed: 15 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04426357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing